Therapeutic potential of Rho-kinase inhibitors in cardiovascular diseases

American Journal of Cardiovascular Drugs

Volumn 5, Issue 1, 2005, Pages 31-39

  Hirooka, Yoshitaka ^a   Shimokawa, Hiroaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; FASUDIL; GLYCERYL TRINITRATE; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ANGINA PECTORIS; ARTERIOSCLEROSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY SPASM; DRUG ABSORPTION; DRUG APPROVAL; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; ERECTILE DYSFUNCTION; HEADACHE; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; JAPAN; METABOLIC ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; SUBARACHNOID HEMORRHAGE; VASCULAR ENDOTHELIUM; VASOSPASM;

ANGINA PECTORIS; BRAIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RANDOMIZED CONTROLLED TRIALS;

EID: 12744255285     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200505010-00005     Document Type: Review

References (76)

1. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629-35
2. Brandier C, Ming X-F, Yang Z. Small G proteins as novel therapeutic targets in cardiovascular medicine. News Physiol Sci 2003; 18: 18-22
3. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev 2001; 81: 153-208
4. Shimokawa H. Rho-kinase as a novel target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2002; 39: 319-27
5. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 2002; 80: 629-38
6. Madaule P, Axel R. A novel ras-related gene family. Cell 1985; 41: 31-40
7. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-4
8. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177-85
9. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-58
10. Davies SP, Reddy H, Caivano M, et al. Specificity and metabolism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105
11. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999; 43: 1029-39
12. Tachibana E, Harada T, Shibuya M, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir 1999; 141: 13-9
13. 2+-dependent activation of Rho and Rho kinase in membrane depolarization-induced and receptor stimulation-induced vascular smooth muscle contraction. Circ Res 2003; 93: 548-56
14. kip1 expression in the vasculature of hypertensive rats. Circ Res 2001; 89: 488-95
15. Seko T, Ito M, Kureishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003; 92: 411-8
16. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001; 15: 1062-4
17. Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans [published erratum appears in Hypertension 2002; 39: e19]. Hypertension 2001; 38: 1307-10
18. van Nieuw Amerongen GP, van Delft S, Vermeer MA, et al. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho-kinase and protein tyrosine kinases. Circ Res 2000; 87: 3365-40
19. van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW. Role of RhoA and Rho-kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000; 20: E127-33
20. Eto Y, Shimokawa H, Hiroki J, et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol 2000; 278: H1744-50
21. Sawada N, Itoh H, Ueyama K, et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000; 101: 2030-3
22. Shibata R, Kai H, Seki Y, et al. Role of Rho-associated kinase neointima formation after vascular injury. Circulation 2001; 103: 284-9
23. Miyata K, Shimokawa H, Kandabashi T, et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscl Thromb Vasc Biol 2000; 20: 2351-8
24. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 2002; 40: 751-61
25. Vicari RM, Smith W, Chairman BR, et al. A randomized, double-blind, placebo-controlled, phase 2 study: the efficacy of fasudil in patients with stable angina [abstract no. 877]. Eur Heart J 2004; 25: 138
26. Nakamura M, Takeshita A, Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation 1987; 75: 1110-6
27. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1β. Circulation 1997; 96: 4357-67
28. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996; 97: 769-76
29. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation 2000; 101: 1319-23
30. Kandabashi T, Shimokawa H, Miyata K, et al. Evidence for protein kinase C-mediated activation of Rho-kinase in a porcine model of coronary artery spasm. Arterioscl Thromb Vasc Biol 2003; 23: 2209-14
31. Kandabashi T, Shimokawa H, Mukai Y, et al. Involvement of Rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscl Thromb Vasc Biol 2002; 22: 243-8
32. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105: 1545-7
33. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet 1998; 351: 1165-9
34. Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol 2003; 41: 15-9
35. Andersen HR, Maeng M, Thorwest M, et al. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury: insights from a porcine coronary (re)stenosis model. Circulation 1996; 93: 1716-24
36. Tutar E, Ozcan M, Kilickap M, et al. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation 2003; 108: 1581-4
37. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701-6
38. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a swine model in vivo. Cardiovasc Res 2001; 51: 169-77
39. Morishige K, Shimokawa H, Eto Y, et al. Adenovirus-mediated transfer of dominant-negative Rho-kinase induces a regression of coronary arteriosclerosis in pigs in vivo. Arterioscler Thromb Vasc Biol 2001; 21: 548-54
40. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004; 24: 181-6
41. Hattori T, Shimokawa H, Higashi M, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res 2004; 94: 46-52
42. Numaguchi K, Egashira K, Takemoto M, et al. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension 1995; 26: 957-62
43. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99: 278-98
44. Kataoka C, Egashira K, Inoue S, et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39: 245-50
45. Ikegaki I, Hattori T, Yamaguchi T, et al. Involvement of Rho-kinase in vascular remodeling caused by long-term inhibition of nitric oxide synthesis in rats. Eur J Pharmacol 2001; 427: 69-75
46. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-9
47. Laufs U, Kilter H, Konkol C, et al. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002; 53: 911-20
48. Sawada N, Itoh H, Yamashita J, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2001; 280: 798-805
49. Ming X-F, Viswambharan H, Barandier C, et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467-77
50. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 2003; 93: 767-75
51. Aoki H, Izumo S, Sadoshima J, et al. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 1998; 82: 666-76
52. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001; 38: 100-4
53. Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21: 868-73
54. Cavapare A, Endolich N, Assaloni R, et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol 2003; 13: 37-45
55. Farber HW, Loscalzo J. Pulmonary arterial hypertension. New Engl J Med 2004; 351 (16): 1655-65
56. Abe K, Shimokawa H, Uwatoku T, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94 (3): 385-93
57. Chitaley K, Wingard CJ, Webb RC, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-22
58. Wingard CJ, Johnson JA, Holmes A, et al. Improved erectile function after Rho-kinase inhibition in a rat model of erectile dysfunction. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1572-9
59. Hashimoto R, Nakamura Y, Kosako H, et al. Distribution of Rho-kinase in the bovine brain. Biochem Biophys Res Commun 1999; 263: 575-9
60. Olenik C, Barth H, Just I, et al. Gene expression of the small GTP-binding proteins RhoA, RhoB, Rac1, and Cdc42 in adult rat brain. Brain Res Mol Brain Res 1997; 52: 263-9
61. Hirose M, Ishizaki T, Watanabe N, et al. Molecular dissection of the Rho-associated protein kinase (p160ROCK)-regulated neurite remodeling in neuroblastoma N1E-115 cells. J Cell Biol 1998; 141: 1625-36
62. Bito H, Furuyashiki T, Ishihara H, et al. A critical role for a Rho-associated kinase, p160ROCK, in determining axon outgrowth in mammalian CNS neurons. Neuron 2000; 26: 431-41
63. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999; 285: 895-8
64. Fischer M, Kaech S, Knutti D, et al. Rapid acti-based plasticity in dendritic spines. Neuron 1998; 20: 847-54
65. Engert F, Bonhoeffer T. Densritic spine changes associated with hippocampal long-term synaptic plasticity. Nature 1999; 399: 66-70
66. 2+-dependent exocytosis through Rho/Rho-associated kinase-dependent pathway. J Neurochem 2000; 75: 708-17
67. Ito K, Hirooka Y, Sakai K, et al. Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 2003; 92: 1337-43
68. Eshima K, Hirooka Y, Shigematsu H, et al. Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 2000; 36: 259-63
69. Ito K, Hirooka Y, Kishi T, et al. Rho/Rho-kinase pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 2004; 43: 156-62
70. Ito K, Hirooka Y, Sagara Y, et al. Inhibition of Rho-kinase in the brainstem augments baroreflex control of heart rate in rats. Hypertension 2004; 44: 478-83
71. Sato M, Tani E, Fujikawa H, et al. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000; 87: 195-200
72. Wickman G, Lan C, Vollrath B. Functional roles of the Rho/Rho-kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasopressin. Circ Res 2003; 92: 809-16
73. Lan C, Das D, Wloskowicz A, et al. Endothelin-1 modulates hemoglobin-mediated signaling in cerebrovascular smooth muscle via RhoA/Rho-kinase and protein kinase C. Am J Physiol Heart Circ Physiol 2004; 286: H165-73
74. Kim I, Leinweber BD, Morgalla M, et al. Thin and thick filament regulation of contractility in experimental cerebral vasospasm. Neurosurgery 2000; 46: 440-7
75. Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective, placebo controlled, double blind trial. J Neurosurg 1992; 76: 571-7
76. Nakashima S, Tabuchi K, Shimokawa S, et al. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subrachnoid hemorrhage. Neurol Med Chir 1998; 38: 805-11